Lu Ping

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital

发表论文 52 篇 · 总被引 351 次 · h-index 4

代表论文

• Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study (2023 · The Lancet Oncology · 被引 312)
• Effects of Environmental Factors on Germination and Emergence of Siam Weed (Chromolaena odorata) (2011 · Procedia Environmental Sciences · 被引 4)
• 591 | NOVEL CHEMOTHERAPY‐FREE INITIAL TREATMENT OF RITUXIMAB PLUS PEGYLATED INTERFERON Α‐2B IN UNTREATED ADVANCED INDOLENT B‐CELL LYMPHOMA: 4‐YEAR FOLLOW‐UP STUDY (2025 · Hematological Oncology · 被引 1)
• Irrational Prosperity, Housing Market, and Financial Crisis: An Empirical Study of Beijing (2012 · 被引 1)
• Screen for specific proteins in the serum of patients with breast cancer using the technique of SELDI-TOF-MS. (2009 · Journal of Chinese clinical medicine · 被引 1)
• A Micro-Quantitative and FFPE-Compatible Workflow for Immunohistochemistry-Guided Spatial Proteomic Analysis of Cellular Subpopulations Within the Tumor Microenvironment (2026 · Bioengineering)